Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.
复制标题
DOI：
10.2217/fca.12.44
复制
发表时间：
2012-07
影响因子：
1.7
通讯作者：
Lipshultz SE
中科院分区：
文献类型：
--
作者：
Harake D;Franco VI;Henkel JM;Miller TL;Lipshultz SE
癌症治疗的进步极大地提高了癌症儿童的存活率。然而，这些相同的化疗或放射治疗可能会导致长期的健康后果。蒽环类药物通常用于治疗儿童癌症，众所周知，它对心脏有毒性，但它们导致心脏损伤的机制仍不完全清楚。较高的蒽环类药物累积剂量和较低的诊断年龄只是确定儿童患心脏毒性风险增加的众多风险因素中的一小部分。虽然心脏毒性可以在任何时候发展，从治疗开始到成年，确定最好的心脏保护措施，以最大限度地减少由蒽环类药物对儿童造成的长期损害，是当务之急。Dexrazoxane是迄今为止唯一已知的药物，它与较少的心功能障碍有关，而不会降低儿童应用蒽环类阿霉素的肿瘤学疗效。鉴于癌症治疗对儿童癌症幸存者的严重长期健康后果，有必要研究提高癌症治疗安全性的新方法。
Advances in cancer treatment have greatly improved survival rates of children with cancer. However, these same chemotherapeutic or radiologic treatments may result in long-term health consequences. Anthracyclines, chemotherapeutic drugs commonly used to treat children with cancer, are known to be cardiotoxic, but the mechanism by which they induce cardiac damage is still not fully understood. A higher cumulative anthracycline dose and a younger age of diagnosis are only a few of the many risk factors that identify the children at increased risk of developing cardiotoxicity. While cardiotoxicity can develop at anytime, starting from treatment initiation and well into adulthood, identifying the best cardioprotective measures to minimize the long-term damage caused by anthracyclines in children is imperative. Dexrazoxane is the only known agent to date, that is associated with less cardiac dysfunction, without reducing the oncologic efficacy of the anthracycline doxorubicin in children. Given the serious long-term health consequences of cancer treatments on survivors of childhood cancers, it is essential to investigate new approaches to improving the safety of cancer treatments.